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Abstract
Identifying altered pathways that are associated with specific cancer types can po-
tentially bring a significant impact on cancer patient treatment. Accurate identifi-
cation of such key altered pathways information can be used to develop novel ther-
apeutic agents as well as to understand the molecular mechanisms of various types
of cancers better. Tri-matrix factorization is an efficient tool to learn associations
between two different entities (e.g., cancer types and pathways in our case) from
data. To successfully apply tri-matrix factorization methods to biomedical prob-
lems, biological prior knowledge such as pathway databases or protein-protein in-
teraction (PPI) networks, should be taken into account in the factorization model.
However, it is not straightforward in the Bayesian setting even though Bayesian
methods are more appealing than point estimate methods, such as a maximum
likelihood or a maximum posterior method, in the sense that they calculate distri-
butions over variables and are robust against overfitting. We propose a Bayesian
(semi-)nonnegative matrix factorization model for human cancer genomic data,
where the biological prior knowledge represented by a pathway database and a
PPI network is taken into account in the factorization model through a finite de-
pendent Beta-Bernoulli prior. We tested our method on The Cancer Genome Atlas
(TCGA) dataset and found that the pathways identified by our method can be used
as a prognostic biomarkers for patient subgroup identification.
1 Introduction
Matrix factorization and its various models (including bi- and tri-matrix factorizations) that utilize
genomic data have been wildly used to identify key altered pathways1 associated with cancer devel-
opment, progress, and patient subgroup identification in cancer genomics. One of key challenges is
how to elaborately include biological prior knowledge, e.g., a pathway database or a protein-protein
interaction (PPI) network, into the factorization models. However, most approaches are based on
regularization approaches, where additional terms that encourage a solution to be similar to what we
expect from the prior knowledge are introduced into an objective function. For example, consider
the case where prior knowledge is given in the form of a PPI network. We expect that parameters
associated with two genes that are connected in the PPI network should have similar values to each
other. We can take this smoothness constraint into account by adding a regularizer term involving a
Laplace matrix constructed from the PPI network to an objective function (e.g., [7]). However, this
approach yields just a point estimate: the uncertainty of the solution is neglected and the methods
often suffer from overfitting. Bayesian approaches are more appealing because they calculate a full
distribution over parameters, instead of a single point estimate. However, it is not straightforward to
take the prior knowledge into account in a factorization model in the Bayesian framework.
1Pathway is defined as ”a series of actions among molecules in a cell that leads to a certain product or a
change in the cell.” (quoted from https://www.genome.gov/27530687/biological-pathways-fact-sheet/). In our
problem setting, a pathway simply means a set of genes that lead a certain biological function.
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We here propose a Bayesian (semi-)nonnegative matrix factorization for human cancer genomic
data, where the biological prior knowledge represented by a pathway database and a PPI network is
incorporated into the factorization through a finite dependent Beta-Bernoulli prior model. We tested
our method on The Cancer Genome Atlas (TCGA) dataset and found that the pathways identified
by our method can be used as a prognostic biomarkers for patient subgroup identification.
Notations: For a matrixA, ai represents its ith row vector, i.e., ai , (Ai,:)
⊤. Similarly, ~aj , A:,j
refers to its jth column vector. The (i, j)th element of the matrixA is expressed by Aij .
2 Related work
We assume that observations are given in a form of matrix, X ∈ RN×D, where N and D are
the number of samples and input features respectively. The goal of tri-matrix factorization is to
approximate the matrixX by a multiplication of three sub latent matrices, such that
X ≈ USV ⊤, (1)
where U ∈ RN×K , S ∈ RK×R and V ∈ RR×D . Here, K and R are set to smaller numbers
compared to N and D. One can add further constraints based on the properties of the observations
and available prior knowledge. In fact, most of previous work assumes that the observation matrix is
non-negative and finds all non-negative sub latent matrices [4, 10]. However, in this paper, we relax
this restriction. Motivated by [3], we assume thatX is real-valued and that the sub matrices,U and
S, are still non-negative but V is real-valued, which will be explained in detail in the next section.
Nonnegative matrix factorization methods, including the bi-matrix and the tri-matrix factorization
models, have been applied to many different biological problems (please see references in [2]). In
particular, in [7] the authors use the nonnegative tri-matrix factorization model to identify pathways
that are relevant to human cancer, which is the same goal as ours. The method also involves a path-
way database and a PPI network to learn the latent matrices in the regularization approach. However,
this approach gives us just a single point estimate. Furthermore, the regularized coefficients should
be pre-specified (tuned) by users. For large-scale data problems, it requires heavy-computational
burden when we find optimal values for regularized coefficients via cross-validation.
A Bayesian nonnegative tri-matrix factorization approach has been proposed [1], where exponential
prior distributions are placed on nonnegative latent matrices and their posterior distributions are
calculated by Gibbs sampling or the variational inference. However, the method does not consider
how to use available biological prior knowledge to learn the sub-matrices in the factorization model.
3 Bayesian (semi-)nonnegative matrix tri-factorization
We propose a Bayesian (semi-)nonnegative matrix factorization for human cancer genomic data,
where the prior knowledge represented by a pathway database and a PPI network is taken into
account in the factorization through a finite dependent Beta-Bernoulli prior model. One can consider
our method as an extension of the work in [7] in the Bayesian framework. Thus, our method shares
several nice properties inherited from Bayesian approaches. Furthermore, unlike the work in [7], we
use gene expression data, instead of mutation data (since it usually yields a highly sparse observation
matrix). For gene expression data, the observation matrixX includes negative values (it is same for
other types of genomic data, such as copy number, miRNA expression etc). As mentioned earlier,
we extend the concept of the semi-negative factorization in [3] to the tri-matrix factorization case,
where a certain latent matrix is allowed to have negative values. However, our method can be applied
to nonnegative cases as well with minor changes (placing nonnegativity priors on all latent matrices).
Now, we assume the matrixX is gene expression data measured from patients: the (i, j)th element
inX ,Xij , represents an expression value at the jth gene from the ith patient sample. Furthermore,
we constructU from patient-cancer-type information: K is the number of known cancer types and
Uij = 1 indicates the ith patient has jth cancer type. We assume that each patient has a single
cancer type, i.e.,
∑K
k=1 Uik = 1 and Uik ∈ {0, 1}. In addition, let denote Z
0 ∈ RD×R by a given
pathway database where R is the number of pathways in the database and Z0jr = 1 if the jth gene is
annotated in rth pathway as a member. With the binary matrix Z0, our factorization model is:
X ≈ US
(
Z0 ◦ V
)⊤
(2)
where ◦ is Harmardard operator, i.e., element-wise multiplication operator. In our model (2), the
matrix V is a set of basis (row) vectors and only few elements (corresponding to member genes of
each pathway) in the matrix can contribute to the factorization due to the element-wise multiplica-
tion with the binary matrixZ0. Then, the matrixS represents associations between cancer types and
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pathways, where each element of Sij represents associations between ith cancer type with jth path-
way. Higher values of elements indicate stronger associations between cancer types and pathways.
Thus, our goal can be satisfied by finding an accurate association matrix S from the data.
We next need to specify the likelihood model. We assume it to follow a Gaussian distribution:
Xij ∼ N (Xij |u
⊤
i S
(
zj ◦ vj
)
, γ), γ ∼ Gam(γ|α0a, α
0
b) (3)
where the precision γ (the inverse of the variance) is sampled from a Gamma distribution.
Additional assumptions on the latent matrices are made as follows. With the fixed U , the recon-
structed matrix, i.e., Xˆ = US
(
Z0 ◦ V
)⊤
will have the same valued rows for all the samples that
belong to the same cancer types. To remedy this, we also learn the cluster matrix U from the data:
ui = ζu
0
i + (1− ζ)u˜i, (4)
where u0i is directly from the patient-cancer-type data, ζ > 0 and u˜i ∈ R
K is also a probability vec-
tor to be learned, i.e.,
∑K
k=1 U˜ik = 1 and Uik ≥ 0. The closer ζ to 1, the more we rely on the given
information. Next, an element in S is sampled from an Exponential distribution (nonnegativity):
Skr ∼ Expon(Skr|λ
S0
kr ). (5)
Furthermore, as mentioned earlier, since the observation matrix is real valued, we allow V to have
non-negative values. We assume each element in V to be sampled from a Gaussian distribution.
Vjr ∼ N (Vjr |µ
V 0
jr , σ
V 0
jr ). (6)
Since a pathway database could be incomplete, we also learn a binary matrix Z ∈ RD×R based
on Z0 with a PPI network (in a form of a graph, G). To do this, we place a finite dependent Beta-
Bernoulli prior distribution onZ [9]. For better understating, we first consider a finite Beta-Bernoulli
prior distribution without considering the dependency, which is given in a hierarchical way:
Zjr ∼ Bernoulli n(πr), πr ∼ Beta(βa/R, 1), (7)
The expected number of non-zero entries inZ isDβa/(1+βa/R) and this parametric (finite) model
becomes Indian Buffet process when R goes to infinity [5]. We can naturally think that two genes
may work together if they are connected in G. In other words, two connected genes in the graph
would be active together in a pathway. First, let us defineG ∈ RD×R as a matrix containingR sets
of function values and assume that each column, ~gr, follows a Gaussian process given by
~gr|G ∼ N (~gr|0,L) (8)
where L = I − D−1/2AD−1/2 is a normalized Laplacian matrix. we now couple a Bernoulli
variable Zjr and a function valueGjr using the same method in [8, 9]:
Zjr = I
[
Gjr < Φ
−1(πr)
]
, Gjr ∼ N
(
0, 1
)
, πr ∼ Beta
(
βa/R, 1
)
, (9)
whereΦ is a cumulative Gaussian distribution. For example, Zjr and Zj′r are more likely to be both
1 or 0 if Gjr andGj′r are close to each other. For simplicity, we define π¯r = Φ
−1(πr):
p(π¯r) = Beta
(
Φ(π¯r)|βa/R, 1
)
N (π¯r |0, 1). (10)
Lastly, we defineM = {(j, r)|Z0jr = 1} as nonzero entries in Z
0 and try to make sure that all the
corresponding entries in {Zjr|(j, r) ∈M} are also close to 1 during training.
4 Variational inference
We approximately compute posterior distributions of all the variables in the variational inference
framework. First, the variational distributions are assumed to be fully factorized:
q(γ,S,Z,V , g,pi) = q(γ)
( K∏
k=1
R∏
r=1
q(Skr)
)( D∏
j=1
R∏
r=1
q(Vjr)q(Zjr)q(Gjr)
)( R∏
r=1
q(π¯r)
)
. (11)
The form of each variational distribution is as follows
q(γ) = Gam(γ|αa, αb), q(Skr) = T N (Skr |µ
S
kr , σ
S
kr), q(Vjr) = N (Vjr |µ
V
jr , σ
V
jr),
q(Zjr) = p(Zjr|πr, Gjr), q(Gjr) = N (Gjr |µ
g
jr , σ
g
jr), q(π¯r) = N (π¯r |µ
p¯i
r , σ
p¯i
r ). (12)
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Note that q(Zjr) is fully determined by π¯ andGjr (also refer (15)). Denote a set of all the variables
and the parameters byΘ = {γ, U˜ ,S,V ,G, p¯i}. Then the variational distributions can be computed
by maximizing the lower bound on the likelihood
max
q(Θ)
L(q) =
∫
q(Θ) log
p(X,Θ)
q(Θ)
dΘ (13)
such that q(Zjr = 1) = 1, ∀ (j, r) ∈M, (14)
where a marginal distribution of an Bernoulli variable Zjr, q(Zjr = 1), can be calculated as follows
q(Zjr = 1) = Ep(Zjr |gjrpir)q(Gjr)q(p¯ir)
[
Zjr
]
= Φ
((
µp¯ir − µ
g
jr
)
/
√
σp¯ir + σ
g
jr
)
(15)
The variational distributions, q(γ), {q(Skr)} and {q(Vjr)}, can be updated in closed form (by the
similar manner as in [1]). With defining new variables, U˜ik = exp(θ
U
ik)/
∑K
k′=1 exp(θ
U
ik′ ), the
matrix U˜ (obtained by optimizing {θUik}) can be found by any unconstrained gradient methods. For
q(p¯i) and q(G), we solve the following regularization problem,
max
q(p¯i),q(G)
L(q) + ξ
∑
(j,r)∈M
log q(Zjr = 1) (16)
where ξ > 0 is a regularization coefficient. Here, the regularization function (a sum of the negative
cross entropy) is defined on the posterior distributions over {Zjr|(j, r) ∈ M} [11].
5 Experimental results
We tested our method on the gene expression (mRNA) data from TCGA2. We further removed
several cancer types that have small number patient samples (less than 200). The number of cancer
types and patient samples wereK = 20 and N = 8, 444, respectively. We used ’biocarta’ pathway
database3 where the number of pathways is R = 217. We also downloaded a PPI network from
BioGRID4. After intersecting all the datasets, the number of the common genes was D = 1, 152.
After all the parameters (including the latent matrices) were learned, we selected the top-5 ranked
pathways for the kth cancer type based on the mean values of the elements in the kth row vector of
S. All the member genes in these pathways were used for gene signature (biomakers) for the patient
stratification of that cancer type. For each cancer type, we performed consensus clustering on the
TCGA gene expression again (500 K-means repetition with bootstrapping [6]) and finally reported
two representative results. As shown in Figure 1, there is a clear separation between the two groups,
which suggests that the pathways identified by our method can be used as prognostic biomarkers.
(a) (b)
Figure 1: Kaplan-Meier plot for (a) KIRC (log-rank p-val = 3.51e−5) and LGG (p-val = 1.60e−17).
2The data was downloaded from CBioportal (http://www.cbioportal.org/). The downloading option was
’TCGA cancer type rna seq v2 mrna’.
3 the data is available from http://software.broadinstitute.org/gsea/msigdb/collections.jsp
4https://thebiogrid.org/. The version is BIOGRID-ORGANISM-Homo sapiens-3.4.153
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